
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Singapore - Just as the skin of a newborn differs from the skin of a young child, so too does the skin of premature infants born at 24 weeks differ from the skin of infants born later.